BioPharma Resources

Drug Trial Radar · NCT03334747

Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.

A Phase 2, Multi-center, Randomized, Open-label, Dose-escalation Study to Determine Safety of Single (QD) and Multiple (3 QD) Doses of KAE609, Given to Adults With Uncomplicated Plasmodium Falciparum Malaria.

Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

188

Actual

Start

Nov 16, 2017

Primary completion

Nov 23, 2019

Study completion Nov 23, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
Collaborators
Wellcome Trust
First posted
Nov 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

KAE609 will be evaluated primarily for hepatic safety of single and multiple doses in sequential cohorts with increasing doses.This study aims to determine the maximum safe dose of the investigational drug KAE609 in malaria patients.

Conditions

  • Malaria

Interventions

  • KAE609Drug

    Exploration of different doses of KAE609 to establish safety profile.

  • CoartemDrug

    Control Arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least 2 CTCAE Grades Increase From Baseline in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)Time frame: Day 29

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Lambaréné, Gabon

  • Novartis Investigative Site

    Kintampo, Ghana

  • Novartis Investigative Site

    Navrango, Ghana

  • Novartis Investigative Site

    Bamako, Mali

  • Novartis Investigative Site

    Sotouba, Mali

  • Novartis Investigative Site

    Kigali, Rwanda

  • Novartis Investigative Site

    Bushenyi, Uganda

  • Novartis Investigative Site

    Kampala, Uganda

  • Novartis Investigative Site

    Tororo, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.